Eight published clinical trials and more than twenty-eight ongoing trials have targeted programmed death 1 (PD-1) or programmed death ligand 1 (PD-L1) alone or in combination with chemotherapy or radiotherapy to seek better responses to esophageal squamous cell carcinoma (ESCC) [3,4]. Here, CD274 is linked to esophageal squamous cell carcinoma.